Management Team
Shao Yan, General Manager
Graduated from Peking University School of Pharmaceutical Sciences
• For 20 years, Ms. Shao has led and participated in pharmaceutical R & D,biochemical and immune technology R & D and clinical technology in pharmaceutical field; has led and participated in pharmaceutical R & D, industrial transformation and patent registration and application of dozens of new drugs, sustained-release and controlled-release preparations and injections;
• Lead and participated in the development and market transformation of several biochemical and immune technology related kits;
• Rich experience in project management and enterprise management, as well as pharmaceutical product marketing experience. She has worked in famous pharmaceutical enterprises or R & D companies at home and abroad, such as Venturepharma, Livzon pharmaceutical, Sangon Biotech (Shanghai).
• For 20 years, Ms. Shao has led and participated in pharmaceutical R & D,biochemical and immune technology R & D and clinical technology in pharmaceutical field; has led and participated in pharmaceutical R & D, industrial transformation and patent registration and application of dozens of new drugs, sustained-release and controlled-release preparations and injections;
• Lead and participated in the development and market transformation of several biochemical and immune technology related kits;
• Rich experience in project management and enterprise management, as well as pharmaceutical product marketing experience. She has worked in famous pharmaceutical enterprises or R & D companies at home and abroad, such as Venturepharma, Livzon pharmaceutical, Sangon Biotech (Shanghai).
Peter Xue, Deputy General Manager
Graduated from the clinical major of Shaanxi University of Chinese medical
• 20-year involvement in medical research and development, and management; led and got involved in clinical trials and registration application of over ten new drugs;
• Once served in medical research institutes; was responsible for institute/hospital subject management; attended “1035 project” management of the Ministry of Science and Technology;
• Got involved in the establishment, research and development and clinical trial of multiple new drug projects in research institutes and pharmaceutical enterprises;
• Had worked in a domestic Sino-foreign funded CRO company held management position; got involved in the clinical trial and registration of multiple new drugs.
• 20-year involvement in medical research and development, and management; led and got involved in clinical trials and registration application of over ten new drugs;
• Once served in medical research institutes; was responsible for institute/hospital subject management; attended “1035 project” management of the Ministry of Science and Technology;
• Got involved in the establishment, research and development and clinical trial of multiple new drug projects in research institutes and pharmaceutical enterprises;
• Had worked in a domestic Sino-foreign funded CRO company held management position; got involved in the clinical trial and registration of multiple new drugs.
Gao Hongzhi, Expert of Data Management and Statistics
Main Leader of the Clinical Pharmacology Department of 307 Hospital
• Graduated from the biostatistics major of Second Military Medical University, over 30 years of experience till now;
• Published more than 20 statistical articles on clinical studies of human pharmacokinetics in Chinese pharmacology journal, Chinese pharmacology bulletin, and Chinese New Pharmaceutical Journal.
• Relying on 307 Hospital platform, He has completed a number of research and statistical work on minocycline, norcantharidin, levodropropizine, voriconazole and artemisinin drugs (06Z071) funded by the army's "Eleventh Five Year Plan" command project.
• Graduated from the biostatistics major of Second Military Medical University, over 30 years of experience till now;
• Published more than 20 statistical articles on clinical studies of human pharmacokinetics in Chinese pharmacology journal, Chinese pharmacology bulletin, and Chinese New Pharmaceutical Journal.
• Relying on 307 Hospital platform, He has completed a number of research and statistical work on minocycline, norcantharidin, levodropropizine, voriconazole and artemisinin drugs (06Z071) funded by the army's "Eleventh Five Year Plan" command project.
Wang Dandan, RA Director
Graduated from the China Pharmaceutical University
• Had 16-year experience of drug research and development; familiar with the whole life cycle from drug research and development to registration application, and domestic and foreign drug registration laws and regulations. Responsible for all work of project registration application, industrial policy analysis and interpretation;
• Good at organizing, coordinating and integrating project resources;
• During the company’s development and growth, efficiently led the team to complete registration application of 330 varieties and obtained nearly 200 clinical approvals, including over 10 initial applications and over 10 import registrations.
• Had 16-year experience of drug research and development; familiar with the whole life cycle from drug research and development to registration application, and domestic and foreign drug registration laws and regulations. Responsible for all work of project registration application, industrial policy analysis and interpretation;
• Good at organizing, coordinating and integrating project resources;
• During the company’s development and growth, efficiently led the team to complete registration application of 330 varieties and obtained nearly 200 clinical approvals, including over 10 initial applications and over 10 import registrations.
Xie Daosheng, Medical Director
Medical Master, Graduated from the Peking Union Medical College Hospital
• Had over 10 years of medical experience, once worked with many foreign enterprises; participated and completed the medical design of clinical trials of over 10 innovative drugs (Phase I ~ Phase IV);
• Completed writing of protocols for over 70 PK, tolerance and BE studies;
• Participated in studies of over 10 innovative drugs such as Class 1.1 chemical drugs TKI, CDK4/6 inhibitor, T2DM, mainly covering endocrinology, oncology, and respiratory system.
• Had over 10 years of medical experience, once worked with many foreign enterprises; participated and completed the medical design of clinical trials of over 10 innovative drugs (Phase I ~ Phase IV);
• Completed writing of protocols for over 70 PK, tolerance and BE studies;
• Participated in studies of over 10 innovative drugs such as Class 1.1 chemical drugs TKI, CDK4/6 inhibitor, T2DM, mainly covering endocrinology, oncology, and respiratory system.
Cao Zhao, Clinical Operation Director
• Had 15-year experience of clinical trial project management and team management, rich project management experience, fully participated in many international multi-center projects in fields of infection, endocrinology, oncology and neurology;
• Has rich resources of medical experts;
• Familiar with the important links of new drug clinical research pipeline;
• Has rich resources of medical experts;
• Familiar with the important links of new drug clinical research pipeline;
Contact Us
—
Address: 3rd Floor, Building 11, Zone 4, Hanwei International Plaza, No. 186, South Fourth Ring
E-mail:nhbd@noahpharm.com
Telephone:+86-10-83688374
Copyright©Beijing Noahpharm Co., Ltd. All Rights Reserved
Privacy Policy Label Powered by 300.cn
No. 11010602201211, Anbei, Beijing Public Network
Business License
